Meta: The truth about donanemab, lecanemab and the new class of Alzheimer’s drugs
Illustration of amyloid plaques (orange) among brain cellsScience Photo Library/Alamy In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression,...








